ImetelChat

I think most have seen this on the Janssen site, for those who haven't, I am posting it here. Of interest is a relatively new area of cancer "interception". It seems likely that some change in the evolution/transformation of MDS (and the seeming unmentioned MF) seem to be occurring such that the natural history of the disease can be changed by "interception." Recall also that Imetelstat had a measurable effect on CSC's in MM. Anyway this is from the Janssen site:

Areas of Highest Focus
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)
ABC-subtype Diffuse Large B Cell Lymphoma (DLBCL)
Multiple Myeloma (MM)
Molecular and Cellular Pathways of Interest
Cell surface targets for immune-directed therapy
Immune checkpoint inhibition
Leukemia stem cells
Pathway addiction (genetic alterations, cell-type specific pathways)
Conditional sensitivity (stress, protein-producing tumors)
Targeting of T cells and NK cells to tumors
Identification of novel tumor-specific antigens
Progression from early Multiple Myeloma to MM and from MDS to AML and cancer interception